[News Brief] HUYABIO Reports Positive Phase 3 Results for Advanced Melanoma Therapy
HUYABIO International has announced positive topline results from its global Phase 3 clinical trial evaluating HBI-8000 in combination with nivolumab…
Global PR
[News Brief] Innovent and Spero License Anti-CD40L Antibody for Autoimmune Diseases
Innovent Biologics and Spero Therapeutics have entered into an exclusive licence agreement for IBI355 (SP001), a Phase 2-ready third-generation Fc-silent…
[News Brief] Halozyme and Incyte Partner on Subcutaneous Drug Delivery for Blood Cancer Therapy
Halozyme Therapeutics has entered into a global collaboration and licence agreement with Incyte to develop subcutaneous formulations of INCA033989, a…
[News Brief] Sai Parenterals Renews Australian OTC Supply Agreement
Sai Parenterals’ Australian subsidiary, Noumed Pharmaceuticals, has renewed an exclusive over-the-counter (OTC) medicines supply agreement with one of Australia’s leading…
[News Brief] AstraZeneca Secures Global Licensing Rights to Zegfrovy for Lung Cancer
AstraZeneca has entered into an exclusive global licensing agreement with Dizal Pharmaceutical to acquire worldwide development and commercialisation rights for…
[News Brief] Merck Opens BioReliance Testing Facility in Germany
Merck has opened a 2,000-square-metre BioReliance testing facility at its headquarters in Darmstadt, Germany. The site provides commercial drug substance,…
[News Brief] ICMCM 2026 Gathers Global Chinese Medicine Experts in Hong Kong
The 25th International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM) will take place from 13 to…
[News Brief] MAXONA Pharmaceuticals Receives FDA Clearance for Pain Therapy Trial
MAXONA Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application…
[News Brief] Telix Opens Integrated Radiopharmaceutical Facility in Australia
Telix Pharmaceuticals Limited has opened Telix Manufacturing Solutions North Melbourne (TMSNM), a purpose-built radiopharmaceutical research, manufacturing and treatment facility in…
[News Brief] Cordex Biologics Grants FarmaMondo Distribution Rights for Zemcelpro®
Cordex Biologics has entered into an agreement granting FarmaMondo SA distribution rights for its cell therapy product, Zemcelpro® (dorocubicel), in…